NCT01811576 - Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

August 5, 2013

Study Completion Date

August 5, 2013

Conditions

Growth Hormone Deficiency

Interventions

DRUG

TV-1106

DRUG

Recombinant human growth hormone

Subcutaneous once daily

Trial Locations (23)

1062

Teva Investigational Site 51056, Budapest

1088

Teva Investigational Site 51055, Budapest

1525

Teva Investigational Site 64016, Ljubljana

4012

Teva Investigational Site 51060, Debrecen

5000

Teva Investigational Site 51058, Szolnok

7624

Teva Investigational Site 51059, Pécs

10676

Teva Investigational Site 63044, Athens

11527

Teva Investigational Site 63045, Athens

49100

Teva Investigational Site 80032, Petah Tikva

78278

Teva Investigational Site 80034, Tel Aviv

80336

Teva Investigational Site 32238, Munich

80804

Teva Investigational Site 32237, Munich

91120

Teva Investigational Site 80033, Jerusalem

97239

Teva Investigational Site 10564, Portland

500 05

Teva Investigational Site 54052, Hradec Králové

775 20

Teva Investigational Site 54051, Olomouc

01307

Teva Investigational Site 32239, Dresden

H-9023

Teva Investigational Site 51061, Győr

H-6720

Teva Investigational Site 51057, Szeged

11 000

Teva Investigational Site 61029, Belgrade

826 06

Teva Investigational Site 62017, Bratislava

833 05

Teva Investigational Site 62022, Bratislava

034 91

Teva Investigational Site 62016, Ľubochňa

All Listed Sponsors

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY